Skip to content
HN On Hacker News ↗

Future of Cancer Care Today — Sijbrandij Foundation LLC

▲ 48 points • 1 comments • by gone35 • 3w ago • HN discussion ↗

Pangram verdict · v3.3

We believe that this text is a mix of AI and human-written content.

33 %

AI likelihood · overall

Mixed
69% human-written 31% AI-generated
SEGMENTS · HUMAN 0 of 5
SEGMENTS · AI 1 of 5
WORD COUNT 331
PEAK AI % 82% · §1
Analyzed
Oct 15
backend: pangram/v3.3
Segments scanned
5 windows
avg 66 words each
Distribution
69 / 31%
human / AI fraction
Verdict
Mixed
Pangram v3.3

Article text · 331 words · 5 segments analyzed

Human AI-generated
§1 AI · 82%

There is more science available to cancer patients than what one care team can keep up with. New diagnostics, treatments, trials, and suppliers keep emerging, and when standard of care runs out, patients are usually left to figure out what else might be possible on their own.

§2 Mixed · 39%

Future of Cancer Care Today (FCCT) helps cancer patients and their families connect the dots. Our PhD-led team surfaces diagnostic and treatment options relevant to a patient's case, including those beyond standard of care, and finds vetted suppliers and providers who work beyond standard protocols.

§3 Mixed · 68%

FCCT does not replace doctors or make treatment decisions. We create playbooks and curate resources to help families ask better questions, so they can walk into the next conversation with a fuller picture. Free for patients. Important to know. Future of Cancer Care Today is not a medical provider. We do not diagnose, prescribe, or direct treatment. We provide a non-clinical support layer focused on information, education, and decision support, intended to complement your relationship with your care team. Some materials may be generated with the support of artificial intelligence and should be reviewed with your medical providers before informing any care decisions.

§4 Mixed · 37%

All decisions regarding your care belong to you and your doctor. GET IN TOUCH WITH US A curated body of suppliers, clinicians, and research groups we have encountered through our work.Listings are informational only.

§5 Mixed · 49%

FCCT does not endorse, certify, or control these suppliers, and inclusion does not imply a referral or recommendation. Please verify details directly with the supplier and discuss any next steps with the patient’s care team. SUPPLIERS AND CARE PROVIDERSupdated regularly Services that preserve a patient's tumor tissue at biopsy or surgery for future testing, including therapies that may not yet exist at the time of collection.SpeciCare (US). Patient-orderable. StoreMyTumor (US, Europe). Patient-orderable. Kernis Health (US). Patient-orderable. Even One Ventures company. Tests that examine the molecular features of a tumor, including mutations, gene expression, proteins, and biomarkers, to help identify potential treatment targets.